
Professor of Medicine, with tenure
Duke-NUS Faculty Mentor
Third Year Mentor - Clinical Research Study Program (CRSP)
Campus mail:
1149 N Pavilion, Durham, NC 27710
Phone:
(919) 668-1040
My research interests focus on the care of patients with hematologic malignancies, both with and without the use of bone marrow or stem cell transplantation. I focus my research efforts on new approaches to manipulate minimal residual disease.
Recent endeavors have included:
- Phase one trials with novel anti-cancer agents targeting aurora kinases, tyrosine kinases, mtor, VEGF, and raf/ras pathways
- New monoclonal antibodies targeting tumor stroma rather than cellular antigens
- Investigating new antibody targets, i.e. CD123, endoglin, or tenascin for hematologic malignancies
- Aggressive therapy and transplantation for mantle cell lymphoma
- Antiangiogenesis therapy for patients with NHL
- Nonablative allogeneic transplantation therapy with matched or mismatched donors followed by immune modulation
Education and Training
- University of Rochester, M.D. 1991
- Duke University, Medical Resident, Medicine
- Duke University, Fellow in Hematology/Oncology, Medicine
Selected Grants and Awards
- SGI 110 12
- Phase 1b Study of Venetoclax and Alvocidib in Patients with Relapsed/Refractory Acute Myeloid Leukemia
- PF-04449913 (Glasdegib) in Combination with Azacitidine
- Protocol 2215-CL-9100
- Protocol Number NLA-0101-CIN-01
- PRAN-16-52
- Phase 1 study of ER190LI - ARTEMIS T Cells in Relapsed and Refractory CD19 + Non-Hodgkin's Lymphoma
- 2102 HEM 101
- CA212016 BMS
- MEI-011
- AG-120
- Venetoclax (ABT-199/GDC-0199) in combination with Azacitidine
- Phase I/II Study of Lintuzumab-Ac225 AML
- A Phase 3 Multicenter, Randomized, Open Label study of Guadecitabine
- Postdoctoral Training in Genomic Medicine Research
- Phase 1 Study of ABBV-075
- Phase I study of ADCT-301 in CD25+ AML
- TPI-ALV-201
- Efficacy study of Inecalitol in combination with Decitabine in Acute Myeloid Patients unfit for standard chemotherapy
- MEDI D4190C00023
- Transfusion Medicine and Hematology
- A phase 3 study of SGI-110 vs Treatment Choice for AML patients not candidates for chemotherapy
- Phase III study of ASP2215 vs Salvage Chemo in pts with R/R AML with FLT3 mutation
- Breaking B-Cell Tolerance to Produce Antibodies that Eradicate Leukemias and Lymphomas
- Quizartinib AC220-007
- Pathological B Cells: Novel Strategies to Prevent and Treat Chronic GVHD
- SL-401 with AML patients
- A Phase 1 Dose Escalation Study of MDG006 in Patients with Relapsed or Refractory AML
- Phase I Study of ABT-199 in comb w/ Aza or Dec with AML patients ho are > 65 y/o
- Selection of Allogeneic Hematopoietic Cell Donor Based on KIR and HLA Genotypes
- Phase I study of L-asparaginase encapsulated in red blood cells (ERYASP)
- Phase 2 of SY-1425
- Phase II study of SINE (KPT-330) vs SOC in patients with R/R AML
- Development of the Phase I study involving ET190L1-Artemis in CD19 positive blood malignancies
- Phase 3 Guadecitabine (SGI-110-07)
- Stemline Phase II
- Improving Outcomes of Older and Medically Infirm Patients with AML
- Phase I/II Pri-724 for Advanced Myeloid Malignancies
- Phase 1/1b, First-in-Human FLX925 for R/R AML
- Randomized Phase II study of CX-01 combined with standard induction therapy for newly diagnosed AML
- Phase 2, Randomized, Double-Blind, Placebo-Controlled study of Azacitidine with or without Birinapant
- A Multicenter Phase III Rand, open-Label, study of Bosutinib vs Imatinib in adults with newly diagnosed CPCML
- Kalobios Ph1/2 KB004 for EphA3-Expressing Hematologic Malignancies (KB004-01)
- Cancer Biology Training Grant
- Clinical Oncology Research Career Development Program
- Mechanisms of lung injury following autologous BMT
- Mentored Patient-Oriented Research Career Dev Award